IL13RA2 and neoplasm: Additionally, it is also seen that there is the effective killing of GB cancer cells with the NSCs modified with BiTEs, specifically the promotion of T-cell killing of IL13Rα2+ tumor cells by engaging the tumor cell antigen with CD3 epsilon T cells that effectively target them [129].